Withdrawal of cerivastatin from the world market
<p>Abstract</p> <p>Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibroz...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2001-09-01
|
| Series: | Current Controlled Trials in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | http://cvm.controlled-trials.com/content/2/5/205 |
| id |
doaj-b175e7680b3a4525895f8f0f036f8e4c |
|---|---|
| record_format |
Article |
| spelling |
doaj-b175e7680b3a4525895f8f0f036f8e4c2020-11-24T22:50:02ZengBMCCurrent Controlled Trials in Cardiovascular Medicine1468-67082001-09-012520520710.1186/cvm-2-5-205Withdrawal of cerivastatin from the world marketPitt BertramFurberg Curt D<p>Abstract</p> <p>Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.</p> http://cvm.controlled-trials.com/content/2/5/205cerivastatindrug safetyLDL cholesterolrhabdomyolysisstatins |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Pitt Bertram Furberg Curt D |
| spellingShingle |
Pitt Bertram Furberg Curt D Withdrawal of cerivastatin from the world market Current Controlled Trials in Cardiovascular Medicine cerivastatin drug safety LDL cholesterol rhabdomyolysis statins |
| author_facet |
Pitt Bertram Furberg Curt D |
| author_sort |
Pitt Bertram |
| title |
Withdrawal of cerivastatin from the world market |
| title_short |
Withdrawal of cerivastatin from the world market |
| title_full |
Withdrawal of cerivastatin from the world market |
| title_fullStr |
Withdrawal of cerivastatin from the world market |
| title_full_unstemmed |
Withdrawal of cerivastatin from the world market |
| title_sort |
withdrawal of cerivastatin from the world market |
| publisher |
BMC |
| series |
Current Controlled Trials in Cardiovascular Medicine |
| issn |
1468-6708 |
| publishDate |
2001-09-01 |
| description |
<p>Abstract</p> <p>Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.</p> |
| topic |
cerivastatin drug safety LDL cholesterol rhabdomyolysis statins |
| url |
http://cvm.controlled-trials.com/content/2/5/205 |
| work_keys_str_mv |
AT pittbertram withdrawalofcerivastatinfromtheworldmarket AT furbergcurtd withdrawalofcerivastatinfromtheworldmarket |
| _version_ |
1725673761379713024 |